OncoSec Medical to Present at Prominent Scientific and Investment Conferences in March


OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at several high-profile events in March, including the 27th Annual ROTH Conference and the 5th Annual "Cancer Immunotherapy: A Long- Awaited Reality" Conference.

27th Annual ROTH Conference

Punit Dhillon, President and CEO, will present a corporate overview at the 27th Annual ROTH Conference, which is held March 8-11 in Dana Point, CA. The presentation is scheduled to begin at 8:00 AM PT on Wednesday, March 11th in the Colonnade Room on Track 4.

Each year, the ROTH Conference gathers institutional investors, private equity investors, company executives and service providers to build relationships and provide a platform for networking with existing and potential clients. The conference features presentations from hundreds of public and private companies in a variety of sectors, including healthcare, business services, consumer, and industrial growth. For more information, please visit: http://www.roth.com.

OncoSec invites investors and the general public to view and listen to the live webcast. At the time of the presentation, the webcast will be available via the following link: http://wsw.com/webcast/roth29/oncs. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days on OncoSec’s website: http://www.oncosec.com.

5th Annual "Cancer Immunotherapy: A Long- Awaited Reality" Conference

Robert H. Pierce, MD, Chief Scientific Officer, will present a corporate overview as well as a lecture, entitled: "Taking the Fight to the Tumor: A Rationale for Intratumoral Electroporation of Immunomodulators” at MaidStone Life Sciences’ 5th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 26th at the New York Academy of Medicine in New York City. Dr. Pierce will also join key opinion leaders to discuss the role of cancer vaccines in a panel discussion, entitled "What Is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T-Cell Immunotherapies?”

The annual "Cancer Immunotherapy: A Long-Awaited Reality" is a single-day conference that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions and showcase leading companies in the field of cancer immunotherapy. The conference format is designed to foster networking, knowledge sharing, and learning in an interactive environment. For more information, please visit: http://www.maidstonels.com/conference.html.

About OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


OncoSec Medical Inc.
Investor Relations:
Jordyn Kopin, 855-662-6732
Media Relations:
Mary Marolla, 855-662-6732

Source: OncoSec Medical Inc.